Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03544099
Recruitment Status : Not yet recruiting
First Posted : June 1, 2018
Last Update Posted : June 1, 2018
Sponsor:
Collaborators:
National Taiwan University Hospital
Koo Foundation Sun Yat-Sen Cancer Center
Chang Gung Memorial Hospital
Taichung Veterans General Hospital
China Medical University Hospital
Changhua Christian Hospital
National Cheng-Kung University Hospital
Information provided by (Responsible Party):
National Health Research Institutes, Taiwan

Brief Summary:
This is a single-arm, multi-center, open-label, phase II trial to examine the efficacy of pembrolizumab for prolonging the one-year disease free survival in nasopharyngeal carcinoma patients with solely detectable EBV DNA after curative chemoradiation. Sixty-three patients will be enrolled in the trial.

Condition or disease Intervention/treatment Phase
Immunotherapy With Pembrolizumab for Nasopharyngeal Carcinoma Patients Drug: Pembrolizumab Phase 2

Detailed Description:

This phase II study is aimed to prove the efficacy of adjuvant therapy with pembrolizumab for nasopharyngeal carcinoma patients with detectable plasma EBV DNA after curative chemoradiation.

Nasopharyngeal cancer was a malignancy related to Epstein-Barr virus infection. It was a malignancy endemic in Southeast Asia, Taiwan, and China [1, 2]. The primary treatment was chemoradiation. The three-year disease free survival was around 50-60% for locally-advanced (stage IVA, IVB) NPC[1, 3-5]. Adjuvant chemotherapy after curative chemoradiation is a strategy to improve disease control rate for advanced NPC. However, two phase III trials in Taiwan (TCOG 1394) and China failed to prove its efficacy on improving disease control and overall survival [6, 7]. How to identify patients who are truly at risk is an important question for the therapy of advanced NPC.

Plasma EBV DNA copy number is a biomarker predicting the recurrent risk of nasopharyngeal cancer. A higher level of plasma EBV DNA before chemoradiation is related to a poorer prognosis [5]. A detectable EBV DNA after chemoradiation, which is a hint for occult residual or metastatic disease, is a strong predictor for early recurrence [5, 8-12]. The relapse free survival at two years for patients with detectable plasma EBV DNA (> 0 copies/mL) was around 20%. The results of other similar trials are summarized on table 1.

Cancer cells escaped from the immune surveillance by several mechanisms. One of them is activating immune inhibitory pathway by "immune checkpoints" [13]. Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) is one immune checkpoint axis to regulate immune response against cancer. Pembrolizumab (MK-3475), an anti-PD-1 antibody, had a good activity against melanoma [14] and other types of cancers [15, 16]. The toxicity profiles were tolerable. In the Keynote-028 phase Ib trial, pembrolizumab showed good clinical activity against recurrent or metastatic NPC [17]. The overall response rate is 22%, and the disease control rate is 77.8%. This data is encouraging for further clinical trials of pembrolizumab for NPC.

PD-1/PD-L1 axis has an important role for the resistance of chemoradiation[18]. In patients refractory to chemoradiation, the expression of PD-1 and PD-L1 increased in the tumor. In animal model, sequential administration of anti-PD-1 after radiation significantly improved the progression free survival in mice with tumors [19]. This concept supports the investigator's sequential design for high-risk NPC patients.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 63 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Interventional
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial
Estimated Study Start Date : July 1, 2018
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Pembrolizumab for NPC patients
Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
Drug: Pembrolizumab
Pembrolizumab 200mg Intravenous Solution
Other Name: KEYTRUDA




Primary Outcome Measures :
  1. prolong one-year disease free survival (DFS-1y) [ Time Frame: 5 years ]
    To examine the efficacy of pembrolizumab to prolong one-year disease free survival (DFS-1y) in nasopharyngeal carcinoma (NPC) patients with detectable plasma Epstein-Barr virus (EBV) DNA after curative chemoradiation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be willing and able to provide written informed consent/assent for the trial.
  2. Be more than 20 years of age on day of signing informed consent.
  3. Have a performance status of 0 or 1 on the ECOG Performance Scale
  4. Demonstrate adequate organ function as defined in Table 2

    • Hematological
    • Absolute neutrophil count (ANC) ≥1,500 /mcL
    • Platelets ≥100,000 / mcL
    • Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment)
    • Renal Serum creatinine OR Measured or calculateda creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
    • Hepatic
    • Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
    • AST (SGOT) and ALT (SGPT)≤ 2.5 X ULN
    • Albumin >2.5 mg/dL
    • Coagulation
    • International Normalized Ratio (INR) or Prothrombin Time (PT)
    • Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants ≤1.5 X ULN unless subject is receiving anticoagulant therapyas long as PT or PTT is within therapeutic range of intended use of anticoagulants aCreatinine clearance should be calculated per institutional standard.
  5. Histology proven nasopharyngeal carcinoma. Biopsy at nasopharynx is mandatory.
  6. Completing radiotherapy more than 66Gy (curative intent radiotherapy)
  7. Detectable plasma EBV DNA: it is defined by the following criteria:

    1. The first test of plasma EBV DNA: 6-8 weeks after the last dose of radiotherapy.
    2. If the first test of plasma EBV DNA is detectable:

      • Within the "linear dynamic range": eligible by one single EBV DNA testing
      • Lower than the "linear dynamic range": it should be repeated within 2-4 weeks after the report day of first test of plasma EBV DNA. If both results are detectable, the patient is eligible
      • *The "linear dynamic range" is defined as the highest to the lowest quantifiable copy number established by means of a calibration curve (MIQE guidelines, 7.4.2 section, Clin Chem. 2009;55(4):611-22)
  8. No detectable residual disease or distant metastases after imaging studies: The following examinations should be completed within 28 days after the report day of detectable plasma EBV DNA. If a repeated test of plasma EBV DNA is necessary by criteria 7, the following examination should be completed within 28 days after the report day of the repeated plasma EBV DNA test.

    1. For locally residual disease, head and neck MRI should be completed. For patients who cannot take MRI, CT scan with and without contrast should be completed.
    2. For distant metastases, one of the following studies should be completed.

      • Whole body PET-CT scan (if the modality is available)
      • CT scan with and without contrast of chest and abdomen, and bone scan
  9. Female subject of childbearing potential should have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  10. Female subjects of childbearing potential (Section 5.5.2) must be willing to use an adequate method of contraception as outlined in Section 5.5.2 - Contraception, for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
  11. Male subjects of childbearing potential (Section 5.5.2) must agree to use an adequate method of contraception as outlined in Section 5.5.2- Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

Exclusion Criteria:

  • The subject must be excluded from participating in the trial if the subject:

    1. Other malignancies diagnosed before or concurrently with the diagnosis of NPC.
    2. Take chemotherapy or other anti-cancer agents after curative chemoradiation.
    3. Documented residual / recurrent local disease or distant metastases after completing chemoradiation.
    4. Plasma EBV DNA is un-detectable.
    5. Unresolved grade 2 or more acute toxicities related to chemoradiation
    6. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
    7. Hypersensitivity to pembrolizumab or any of its excipients.
    8. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Topical or inhaled steroids is not considered as systemic treatment.
    9. Has known history of pneumonitis requiring steroids, or any evidence of active, non-infectious pneumonitis
    10. Has an active infection requiring systemic therapy 14 days before signing informed consent.
    11. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
    12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
    13. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
    14. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
    15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
    16. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
    17. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03544099


Contacts
Layout table for location contacts
Contact: Ya-Ling Wu, BS 886-3-7246166 ext 35119 yalin@nhri.org.tw
Contact: Ruey-Long Hong, PhD 0972-651674 rlhong@ntu.edu.tw

Locations
Layout table for location information
Taiwan
Changhua Christian Hospital Not yet recruiting
Changhua, Taiwan
Sub-Investigator: Hsuan-Yu Lin, MD         
Sub-Investigator: Ching-Yeh Lin, MD         
Sub-Investigator: Li-Chung Hung, MD         
Sub-Investigator: Tung-Hao Chang, PhD         
Sub-Investigator: Kuan-Ming Lai, MD         
Sub-Investigator: Chuan-Cheng Wang, MD         
Sub-Investigator: Cheng- Shyong Chang, MD         
Chang Gung Memorial Hospital Not yet recruiting
Linkou, Taiwan
Sub-Investigator: Hung-Ming Wang, MD         
Sub-Investigator: Ngan-Ming Tsang, MD         
Sub-Investigator: Chi-Ting Liau, MD         
Sub-Investigator: Cheng-Lung Hsu, PhD         
Sub-Investigator: Chia-Hsun Hsieh, MD         
Sub-Investigator: Tung-Chieh Chang, Master         
Sub-Investigator: Kang-Hsing Fan, MD         
Sub-Investigator: Chien-Yu Lin, PhD         
Sub-Investigator: Bing-Shen Huang, MD         
Sub-Investigator: Shu-Hang Ng, MD         
Sub-Investigator: Tzu-Chen Yen, MD         
China Medical University Hospital Not yet recruiting
Taichung, Taiwan
Sub-Investigator: Ching Yun Hsieh, MD         
Sub-Investigator: Ming-Yu Lien, MD         
Taichung Veterans General Hospital Not yet recruiting
Taichung, Taiwan
Sub-Investigator: Jin-Ching Lin, PhD         
Sub-Investigator: Yi-Chun Liu, MD         
Sub-Investigator: Jing-Wei Lin, MD         
Sub-Investigator: Chuan Li, MD         
National Cheng Kung University Hospital Not yet recruiting
Tainan, Taiwan
Sub-Investigator: Chia-Jui Yen, PhD         
Sub-Investigator: Shang-Yin Wu, PhD         
Sub-Investigator: Kwang-Yu Chang, PhD         
Sub-Investigator: Hui-jen Tsai, PhD         
Sub-Investigator: Nai-Jung Chiang, MD         
Sub-Investigator: Shang-Hung Chen, PhD         
Koo Foundation Sun Yat-Sen Cancer Center Not yet recruiting
Taipei, Taiwan
Sub-Investigator: Jia-Shing Wu, MD         
Sub-Investigator: Yu-Chen Tsai, MD         
Sub-Investigator: Hsin-Hsuan Chen, PhD         
National Taiwan University Hospital Not yet recruiting
Taipei, Taiwan
Sub-Investigator: Hsiang-Fong Kao, MD         
Sub-Investigator: Bin-Chi Liao, MD         
Sponsors and Collaborators
National Health Research Institutes, Taiwan
National Taiwan University Hospital
Koo Foundation Sun Yat-Sen Cancer Center
Chang Gung Memorial Hospital
Taichung Veterans General Hospital
China Medical University Hospital
Changhua Christian Hospital
National Cheng-Kung University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Ruey-Long Hong, PhD National Taiwan University Hospital

Layout table for additonal information
Responsible Party: National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier: NCT03544099     History of Changes
Other Study ID Numbers: T1317
First Posted: June 1, 2018    Key Record Dates
Last Update Posted: June 1, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Health Research Institutes, Taiwan:
nasopharyngeal carcinoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Nasopharyngeal Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Nasopharyngeal Neoplasms
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Carcinoma
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents